The BBB (blood brain barrier) protects the brain but it also impedes the transport of neuropharmaceuticals into the brain. cOFM is a unique tool to investigate brain pharmacokinetics (PK) and pharmacodynamics (PD) with an intact BBB in preclinical studies. cOFM studies provide data for drug development as well as unique insights into brain metabolism and signaling.
Our cOFM Services
cOFM is characterized by its capability to sample cerebral ISF (interstitial fluid) while maintaining an intact BBB.
For cOFM experiments, the BBB is allowed to heal and to re-establish for 2 weeks after cOFM probe implantation. cOFM sampling is thus always performed with an intact BBB. During sampling, the cOFM probe is continuously perfused with a physiological fluid (perfusate). The perfusate exchanges molecules with the cerebral ISF along the exchange area at the tip of the cOFM probe, resulting in diluted and also unfiltered cerebral ISF samples, as no membrane is involved. The collected cerebral ISF samples contain all molecules present in the brain tissue without restriction due to size or inherent chemical properties including drugs, proteins and antibodies.
Further, longitudinal sampling for up to several weeks yields time-resolved, high-quality data that deliver PK and PD concentration profiles.
Dr. Joanna Hummer and Dr. Florie Le Prieult share insights into cOFM's use and utility in the broader neuroscience field and specifically for the development of drugs for neurodegenerative diseases.
Presentation with Speaker Notes
HEALTH – Institute for Biomedical Research and Technologies
Neue Stiftingtalstrasse 2/Entrance A/Third Floor
Phone: +43 316 876-4000
Fax: +43 316 8769-4000